O
Orum Therapeutics Inc
KOSDAQ:475830
Orum Therapeutics Inc
KOSDAQ:475830
Price:
119 900
KRW
2.04%
Market Cap:
₩2.5T
Balance Sheet
Balance Sheet Decomposition
Orum Therapeutics Inc
Orum Therapeutics Inc
Balance Sheet Decomposition is not available for
Orum Therapeutics Inc
Orum Therapeutics Inc
Balance Sheet
Orum Therapeutics Inc
Orum Therapeutics Inc
Currency: KRW
| Dec-2022 | Dec-2023 | Dec-2024 | ||
|---|---|---|---|---|
| Assets | ||||
| Cash & Cash Equivalents |
11 276
|
126 658
|
19 700
|
|
| Cash Equivalents |
11 276
|
126 658
|
19 700
|
|
| Short-Term Investments |
810
|
0
|
97 996
|
|
| Total Receivables |
106
|
535
|
2 738
|
|
| Accounts Receivables |
0
|
375
|
2 442
|
|
| Other Receivables |
0
|
160
|
296
|
|
| Other Current Assets |
465
|
254
|
2 076
|
|
| Total Current Assets |
12 656
|
127 448
|
122 510
|
|
| PP&E Net |
5 184
|
32 370
|
30 610
|
|
| PP&E Gross |
5 184
|
32 370
|
30 610
|
|
| Accumulated Depreciation |
3 319
|
5 595
|
6 714
|
|
| Long-Term Investments |
2 552
|
13
|
44
|
|
| Other Long-Term Assets |
890
|
1 952
|
672
|
|
| Total Assets |
21 283
N/A
|
161 783
+660%
|
153 836
-5%
|
|
| Liabilities | ||||
| Accounts Payable |
839
|
3
|
0
|
|
| Accrued Liabilities |
4 932
|
5 138
|
2 079
|
|
| Short-Term Debt |
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
139 206
|
187 951
|
28 122
|
|
| Other Current Liabilities |
2 095
|
1 425
|
1 663
|
|
| Total Current Liabilities |
147 072
|
194 517
|
31 864
|
|
| Long-Term Debt |
1 535
|
23 308
|
208
|
|
| Other Liabilities |
137
|
138
|
0
|
|
| Total Liabilities |
148 744
N/A
|
217 963
+47%
|
32 071
-85%
|
|
| Equity | ||||
| Common Stock |
115
|
460
|
1 843
|
|
| Retained Earnings |
132 290
|
64 072
|
69 813
|
|
| Additional Paid In Capital |
1 035
|
690
|
179 471
|
|
| Other Equity |
3 678
|
6 743
|
10 263
|
|
| Total Equity |
127 461
N/A
|
56 180
+56%
|
121 765
N/A
|
|
| Total Liabilities & Equity |
21 283
N/A
|
161 783
+660%
|
153 836
-5%
|
|
| Shares Outstanding | ||||
| Common Shares Outstanding |
21
|
21
|
21
|
|
Switch to:
Switch to:
See Also
Discover More
